Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
Nuwellis, a medical tech firm, announced on May 14, 2024, the expansion of its pediatric ultrafiltration program using the Aquadex SmartFlow System at a major hospital network in Florida. This initiative expands their current service, which caters to adult heart failure and critical care patients, to include pediatric patients.
Currently, seven hospitals within this network use Nuwellis' technology. This expansion enhances fluid management strategies across the healthcare system for all age groups.
The Aquadex system, FDA-cleared for both adults and pediatric patients over 20 kg, safely removes excess fluid from patients unresponsive to conventional diuretics. The device features customizable fluid removal rates and real-time hematocrit monitoring, important for pediatric care.
- Expansion of ultrafiltration services to pediatric patients in a major Florida hospital network.
- Strengthens collaboration with a large healthcare network, currently using Nuwellis technology in seven hospitals.
- Enhances fluid management strategies across various age groups in the healthcare system.
- Aquadex SmartFlow System offers customizable fluid removal rates and real-time hematocrit monitoring.
- FDA clearance for Aquadex for use in both adults and pediatric patients over 20 kg.
- Potential for wider market penetration and increased revenue through pediatric care expansion.
- Possible financial strain from the cost of expanding services and implementing new programs.
- Dependence on the successful adoption and integration of the new pediatric program by the hospital network.
Insights
The expansion of Nuwellis' Aquadex SmartFlow System® into pediatric care is a significant step in addressing fluid overload management in younger patients. Fluid overload is a serious condition that can lead to complications such as heart failure and respiratory distress. Traditional methods, such as diuretics, often fall short, especially in pediatric cases where managing fluid balance is more intricate due to smaller body volumes.
The key advantage of the Aquadex system is its ability to offer customizable fluid removal rates and real-time hematocrit monitoring. For pediatric patients, these features are critical as they ensure precise and safe fluid removal tailored to each child’s specific needs. This capability not only enhances patient outcomes but also aligns with broader healthcare trends towards personalized and precision medicine.
In the short-term, this expansion may not immediately reflect in significant revenue bumps, but the long-term implications are substantial. As the pediatric use of Aquadex gains traction and demonstrates efficacy, it could lead to wider adoption across other hospital networks, thus driving sustainable growth for Nuwellis.
From a market perspective, Nuwellis' move to expand its ultrafiltration technology to pediatric care at one of the largest hospital networks in Florida is a strategic milestone. The pediatric segment has been underserved in terms of advanced fluid management systems and addressing this gap can position Nuwellis as a leader in this niche market.
This expansion leverages the existing relationship with the hospital network, enhancing trust and ease of integration. The pediatric program could serve as a valuable case study to attract other health systems, fostering organic growth in new markets. Moreover, the successful implementation within a leading hospital network adds credibility and could speed up regulatory clearances for any future pediatric-focused products.
In the long run, tapping into the pediatric market may diversify Nuwellis' revenue streams, reducing dependency on the adult heart failure and critical care segments. This diversification is essential for mitigating risks and stabilizing revenue, particularly in a sector where innovation and regulatory landscapes are constantly evolving.
MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of a new pediatric ultrafiltration program utilizing Nuwellis' Aquadex SmartFlow System® at one of the largest health integrated delivery networks (IDN) in Florida. This program marks an expansion by this network to offer ultrafiltration to its pediatric patients, in addition to its current heart failure and critical care patients.
This launch builds upon the longstanding relationship between this hospital network and Nuwellis. Currently, Nuwellis' technology is utilized by seven hospitals within the network for adult cardiac and critical care. Expanding this collaboration to the pediatric setting allows for a more comprehensive approach to fluid management across the entire healthcare system.
“We are excited to collaborate on the expansion of the pediatric Aquadex ultrafiltration program at this leading hospital network,” said Nestor Jaramillo, Jr., President and Chief Executive Officer at Nuwellis. “The expansion of Aquadex into pediatric care underscores the success of this therapy and the commitment of the network to advance ultrafiltration therapy and improve patient outcomes across all age groups. Additionally, this expansion exemplifies the ongoing and successful execution of our strategy to grow our pediatric customer category.”
Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. The device’s built-in, customizable hematocrit monitoring technology provides real-time measurement of percent blood volume changes that can be tailored to individual patients’ needs. A customizable fluid removal rate is particularly important for pediatric patients who have a small amount of blood in their bodies. The Aquadex system is cleared by the U.S. Food and Drug Administration (FDA) for use in adults and pediatric patients weighing 20 kg or more.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2024 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
CONTACTS
Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
FAQ
What is the significance of Nuwellis' expansion of the pediatric ultrafiltration program?
What technology is used in Nuwellis' pediatric ultrafiltration program?
Which hospital network is expanding its ultrafiltration services with Nuwellis' technology?
How many hospitals currently use Nuwellis' technology within the expanding hospital network?
Is the Aquadex SmartFlow System approved for pediatric use?
